| HRA002598
(Open Access)
|
In this prospective cohort study, ctDNA isolated from 139 plasma samples of 70 mTNBC patients were detected by an NGS panel including 457 cancer-related genes in baseline samples of mTNBCs and monitored the dynamic changes of ctDNA during treatment in 38 patients, further combined with clinical data, treatment responses and survival of patients for statistical analysis.Our study revealed that ctDNA profiling could provide satisfactory insight into the mutation landscape. More importantly, ctDNA is an exceedingly potential biomarker of predicting prognosis and dynamically monitoring treatment response for mTNBCs. |
